This strategy may represent an effective means of ameliorating diet-induced obesity and insulin resistance by exploiting not only hepatic AMPK activation and its subsequent contributions to de novo lipogenesis but also adipose AMPK activation, leading to an increase in the energy-burning capacity of BAT. The gene discussed is PRKAB1; the disease is obesity due to melanocortin 4 receptor deficiency.